Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form
As of April 1st VIVO Scientific Profiles will no longer updated for faculty, and the link to VIVO will be removed from the library website. Faculty profile pages will continue to be updated via Interfolio. VIVO will continue being used behind the scenes to update graduate student profiles. Please contact helplib@scripps.edu if you have questions.
How to download citations from VIVO | Alternative profile options

Highly potent hiv-specific antibody neutralization in vitro translates into effective protection against mucosal shiv challenge in vivo

Academic Article
uri icon
  • Overview
  • Research
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Moldt, B.
  • Rakasz, E. G.
  • Schultz, N.
  • Chan-Hui, P. Y.
  • Swiderek, K.
  • Weisgrau, K. L.
  • Piaskowski, S. M.
  • Bergman, Z.
  • Watkins, D. I.
  • Poignard, Pascal
  • Burton, Dennis

publication date

  • November 2012

journal

  • Proceedings of the National Academy of Sciences of the United States of America  Journal

abstract

  • Most animal studies using passive administration of HIV broadly neutralizing monoclonal antibodies (bnMAbs) have associated protection against high-dose mucosal viral challenge with relatively high serum concentrations of antibody. We recently identified several bnMAbs remarkable for their in vitro potency against HIV. Of these bnMAbs, PGT121 is one of the most broad and potent antibodies isolated to date and shows 10- to 100-fold higher neutralizing activity than previously characterized bnMAbs. To evaluate the protective potency of PGT121 in vivo, we performed a protection study in rhesus macaques. Animals were i.v. administered 5 mg/kg, 1 mg/kg, or 0.2 mg/kg PGT121 24 h before being vaginally challenged with a single high dose of chimeric simian-human immunodeficiency virus (SHIV)(SF162P3). Sterilizing immunity was achieved in all animals administered 5 mg/kg and 1 mg/kg and three of five animals administered 0.2 mg/kg PGT121, with corresponding average antibody serum concentrations of 95 µg/mL, 15 µg/mL, and 1.8 µg/mL, respectively. The results suggest that a protective serum concentration for PGT121 is in the single-digit µg/mL for SHIV(SF162P3), showing that PGT121 can mediate sterilizing immunity at serum concentrations that are significantly lower than those observed in previous studies and that may be achievable through vaccination with the development of a suitable immunogen.

subject areas

  • Animals
  • Antibodies, Monoclonal
  • Antibodies, Neutralizing
  • Female
  • HIV Antibodies
  • HIV Infections
  • HIV-1
  • Humans
  • Immunization, Passive
  • Macaca mulatta
scroll to property group menus

Research

keywords

  • animal model
  • antibody prophylaxis
  • passive transfer
scroll to property group menus

Identity

PubMed Central ID

  • PMC3503218

International Standard Serial Number (ISSN)

  • 0027-8424

Digital Object Identifier (DOI)

  • 10.1073/pnas.1214785109

PubMed ID

  • 23100539
scroll to property group menus

Additional Document Info

start page

  • 18921

end page

  • 18925

volume

  • 109

issue

  • 46

©2022 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support